These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37545464)

  • 1. Global analysis of iron metabolism-related genes identifies potential mechanisms of gliomagenesis and reveals novel targets.
    Zhang J; Zhao L; Xuan S; Liu Z; Weng Z; Wang Y; Dai K; Gu A; Zhao P
    CNS Neurosci Ther; 2024 Feb; 30(2):e14386. PubMed ID: 37545464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
    Ye L; Tong S; Wang Y; Wang Y; Ma W
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
    Wang Q; He Z; Chen Y
    Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration analysis of cell division cycle-associated family genes revealed potential mechanisms of gliomagenesis and constructed an artificial intelligence-driven prognostic signature.
    Yu K; Tian Q; Feng S; Zhang Y; Cheng Z; Li M; Zhu H; He J; Li M; Xiong X
    Cell Signal; 2024 Jul; 119():111168. PubMed ID: 38599441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
    Yang FC; Wang C; Zhu J; Gai QJ; Mao M; He J; Qin Y; Yao XX; Wang YX; Lu HM; Cao MF; He MM; Wen XM; Leng P; Cai XW; Yao XH; Bian XW; Wang Y
    Lab Invest; 2022 Jul; 102(7):741-752. PubMed ID: 35351965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
    Pinto F; Costa ÂM; Andrade RP; Reis RM
    Neurotherapeutics; 2020 Oct; 17(4):2015-2027. PubMed ID: 32785847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
    Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
    Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
    Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
    Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
    He Z; Cheng M; Hu J; Liu L; Liu P; Chen L; Cao D; Tang J
    J Transl Med; 2022 Oct; 20(1):443. PubMed ID: 36183123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
    Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
    Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
    Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
    Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
    Fu J; Peng J; Tu G
    Gen Physiol Biophys; 2022 Jul; 41(4):349-355. PubMed ID: 35938968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H; Cui X
    Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
    Yuan Q; Yang W; Zhang S; Li T; Zuo M; Zhou X; Li J; Li M; Xia X; Chen M; Liu Y
    Mol Med; 2021 Jan; 27(1):7. PubMed ID: 33509092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
    Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
    Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
    [No Abstract]   [Full Text] [Related]  

  • 20. CD90
    Xue BZ; Xiang W; Zhang Q; Wang HF; Zhou YJ; Tian H; Abdelmaksou A; Xue J; Sun MX; Yi DY; Xiong NX; Jiang XB; Zhao HY; Fu P
    Stem Cell Res Ther; 2021 Jul; 12(1):394. PubMed ID: 34256854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.